Cargando…
RANKL/RANK Pathway Abrogates Cetuximab Sensitivity in Gastric Cancer Cells via Activation of EGFR and c-Src [Corrigendum]
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9113662/ https://www.ncbi.nlm.nih.gov/pubmed/35591879 http://dx.doi.org/10.2147/OTT.S371401 |
Ejemplares similares
-
RANKL/RANK pathway abrogates cetuximab sensitivity in gastric cancer cells via activation of EGFR and c-Src
por: Zhang, Xiaomeng, et al.
Publicado: (2017) -
In vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts [Corrigendum]
Publicado: (2019) -
Corrigendum to “Irbesartan Ameliorates Diabetic Nephropathy by Suppressing the RANKL-RANK-NF-κB Pathway in Type 2 Diabetic db/db Mice”
por: Chen, Xiao-Wen, et al.
Publicado: (2016) -
RANKL/RANK promotes the migration of gastric cancer cells by interacting with EGFR
por: Wan, Xing, et al.
Publicado: (2020) -
Corrigendum to “EF24 Suppresses Invasion and Migration of Hepatocellular Carcinoma Cells In Vitro via Inhibiting the Phosphorylation of Src”
por: Zhao, Ran, et al.
Publicado: (2021)